Anavex Life Sciences to Present at Annual Mental Health Parity Addiction Equity Act Roundtable at U.S. Capitol, Washington, D...
December 01 2016 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”)
(Nasdaq:AVXL) today announced that Christopher U. Missling, Ph.D.,
President and Chief Executive Officer, will participate on a panel
comprising 14 representatives from government and industry at the
Fourth Annual Mental Health Parity and Addiction Equity Act
(MHPAEA) Business Roundtable. The panel members will discuss the
current challenges around implementation of the Mental Health
Parity and Addiction Equity Act (MHPAEA) of 2008 and an action
plan. The event will take place on Tuesday, December 6, 2016, at
the U.S. Capitol Visitor Center, in Washington, D.C.
“There is an unmet medical need around brain illnesses such as
Traumatic Brain Injury (TBI) and Post Traumatic Stress Disorder
(PTSD) that must be overcome especially given its impact on our
veterans while addressing two daunting complexities: the biology of
the brain and resources,” said E. Teresa Touey, organizer of the
MHPAEA Business Roundtable. “As a panelist, Dr. Missling brings
relevant drug development experience in complex diseases like
Alzheimer’s, Parkinson’s, Rett syndrome, and other neurological
disorders, so the work that Anavex is doing is immensely
important.”
About the Mental Health Parity and Addiction Equity Act
(MHPAEA)
The Mental Health Parity and Addiction Equity Act of 2008
(MHPAEA) requires group health plans and health insurance issuers
to ensure that financial requirements (such as co-pays,
deductibles) and treatment limitations (such as visit limits)
applicable to mental health or substance use disorder (MH/SUD)
benefits are no more restrictive than the predominant requirements
or limitations applied to substantially all medical/surgical
benefits. MHPAEA supplements prior provisions under the Mental
Health Parity Act of 1996 (MHPA), which required parity with
respect to aggregate lifetime and annual dollar limits for mental
health benefits.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded
biopharmaceutical company dedicated to the development of
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental diseases including Alzheimer’s disease,
other central nervous system (CNS) diseases, pain and various types
of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently
in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73
is an orally available drug candidate that restores cellular
homeostasis by targeting sigma-1 and muscarinic receptors and
successfully completed Phase 1 with a clean safety profile.
Preclinical studies demonstrated its potential to halt and/or
reverse the course of Alzheimer’s disease. It has also exhibited
anticonvulsant, anti-amnesic, neuroprotective and anti-depressant
properties in animal models, indicating its potential to treat
additional CNS disorders, including epilepsy and others. The
Michael J. Fox Foundation for Parkinson’s Research has awarded
Anavex a research grant to develop ANAVEX 2-73 for the treatment of
Parkinson’s disease to fully fund a preclinical study, which could
justify moving ANAVEX 2-73 into a Parkinson’s disease clinical
trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic
receptors, is a promising preclinical drug candidate demonstrating
disease modifications against the major Alzheimer’s hallmarks in
transgenic (3xTg-AD) mice, including cognitive deficits, amyloid
and tau pathologies, and also with beneficial effects on
neuroinflammation and mitochondrial dysfunctions. Further
information is available at www.anavex.com.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Matthew Haines
River East Investor Relations, LLC
917-733-9297
mhaines@rivereastir.com
Media:
Dennis Dobson, Jr.
Dobson Media Group
(203) 258-0159
dennisdobsonjr@dobsonmediagroup.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2024 to May 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2023 to May 2024